Platelet Inhibition with Cangrelor in Patients Undergoing PCI
Robert A. Harrington(Clinical Research Institute), Deepak L. Bhatt(Mount Sinai Hospital), Gilles Montalescot(Maastricht University Medical Centre), Derek P. Chew, Kenneth W. Mahaffey(Cardiovascular Institute of the South), Neal S. Kleiman(Houston Methodist), Simona Skerjanec(Doctors Company (United States)), Dominick J. Angiolillo(University of Florida), Gregg W. Stone(Cardiovascular Institute of the South), Shaun G. Goodman(University of Toronto), Charles V. Pollack, Steven E. McNulty, Harvey D. White(University of Auckland), Maged Amine, F Leisch(Women's General Hospital), William J. French(University of California, Los Angeles), Richard C. Becker(Clinical Research Institute), A. Michael Lincoff(Cleveland Clinic), Keyur Parikh, C. Michael Gibson(Baim Institute for Clinical Research)
Cited by 618
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k